is compounded semaglutide going away Away? Regulatory Updates – PlexusDx The Pros and Cons of

Semaglutide and tirzepatide data from FDA-approved trials (STEP and SURMOUNT programs)

Glycine is one of the most common additions to these compounded preparations

It belongs to a novel class of medicines known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists

Retatrutide is in clinical trials by Eli Lilly, while MOTS-c is largely available through research channels

Industry Funding: From the study, Eli Lilly and Company sponsored the work and was involved in the study design, data collection, data review, data analysis, and drafting of the report

Answering Clinical Questions